The benefit of using epigenetic therapy versus taking the alternative approach of targeting the new dependencies of transformed variants (such as FGFR for mesenchymal variants or AURKA for Rb1-deficient, transformed SCLC) also needs to be clarified. Here, RB1 is linked to small cell lung carcinoma.